SCHEMBL594174

SCHEMBL594174

COc1ccc(Br)c2cc[nH]c12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.40
AHR P35869 1/20 0.38
PRKCI P41743 1/20 0.36
NQO2 P16083 2/20 0.36
ERN1 O75460 1/20 0.36
KDM4E B2RXH2 3/20 0.35
PARP1 P09874 1/20 0.35
MEN1 O00255 1/20 0.35
POLB P06746 1/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35
PKM P14618 1/20 0.35
KMT2A Q03164 1/20 0.35
HTR2A P28223 2/20 0.35
ALDH1A1 P00352 1/20 0.34
HPGD P15428 1/20 0.34
DBH P09172 1/20 0.34
HTR2C P28335 1/20 0.34
MTNR1A P48039 1/20 0.33
MTNR1B P49286 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL594175 0.85 BRD4 (0.40) BRD4AHRNQO2ERN1KDM4E
SCHEMBL593491 0.84 KDM4E (0.42) BRD4NQO2KDM4EMEN1POLB
SCHEMBL10257960 0.78 NQO2 (0.41) BRD4NQO2KDM4EMEN1POLB
SCHEMBL17288068 0.77 P2RX7 (0.39) BRD4KDM4EMEN1POLBGAA
SCHEMBL12422267 0.77 P2RX7 (0.36) BRD4AHRPRKCIKDM4EMEN1
SCHEMBL6194739 0.77 IDO1 (0.50) BRD4KDM4EPARP1MEN1POLB
SCHEMBL9315424 0.77 HIF1A (0.43) KDM4EPARP1MEN1POLBGAA
SCHEMBL29556631 0.77 AHR (0.48) AHRPRKCIPARP1KMT2A
SCHEMBL2124264 0.77 AHR (0.48) AHRPRKCIPARP1KMT2A
SCHEMBL31663248 0.77 AHR (0.35) AHRPRKCIPARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125364-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2026-05-07 US disclosed
US-12595255-B2 Heteroaryl-substituted imidazole derivatives HOFFMANN-LA ROCHE INC. (US) 2026-04-07 US disclosed
US-20240317713-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2024-09-26 US disclosed
US-11964961-B2 Heteroaromatic compounds and their use as dopamine D1 ligands PFIZER INC. (US) 2024-04-23 US disclosed
CN-111116588-B Fused tetracyclic compound and application thereof in medicines 广东东阳光药业股份有限公司 2024-01-16 CN disclosed
EP-4288424-A1 NOVEL HETEROARYL-SUBSTITUTED IMIDAZOLE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2023-12-13 EP disclosed
US-20230373978-A1 HETEROARYL-SUBSTITUTED IMIDAZOLE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2023-11-23 US disclosed
US-11807635-B2 Nitrile derivative that acts as inhibitor of dipeptidyl peptidase 1 and use thereof HAISCO PHARMACEUTICALS PTE. LTD. (SG) 2023-11-07 US disclosed
US-11807635-B2 Nitrile derivative that acts as inhibitor of dipeptidyl peptidase 1 and use thereof HAISCO PHARMACEUTICALS PTE. LTD. (SG) 2023-11-07 US disclosed
US-11773091-B2 6-5 fused rings as C5a inhibitors CHEMOCENTRYX, INC. (US) 2023-10-03 US disclosed
WO-2007062996-A1 3-AMINO-1-ARYLPROPYL INDOLES AND AZA-SUBSTITUTED INDOLES F. HOFFMANN-LA ROCHE AG (CH) 2007-06-07 WO disclosed
WO-2007062996-A1 3-AMINO-1-ARYLPROPYL INDOLES AND AZA-SUBSTITUTED INDOLES F. HOFFMANN-LA ROCHE AG (CH) 2007-06-07 WO disclosed
US-20070123527-A1 3-Amino-1-arylpropyl indoles and aza-substituted indoles and uses thereof ROCHE PALO ALTO LLC 2007-05-31 US disclosed
US-20070123527-A1 3-Amino-1-arylpropyl indoles and aza-substituted indoles and uses thereof ROCHE PALO ALTO LLC 2007-05-31 US disclosed
US-20070123527-A1 3-Amino-1-arylpropyl indoles and aza-substituted indoles and uses thereof ROCHE PALO ALTO LLC 2007-05-31 US disclosed
WO-2007061737-A2 FUSED BICYCLIC mTOR INHIBITORS OSI PHARMACEUTICALS, INC. (US) 2007-05-31 WO disclosed
WO-2007061737-A2 FUSED BICYCLIC mTOR INHIBITORS OSI PHARMACEUTICALS, INC. (US) 2007-05-31 WO disclosed
US-20070112005-A1 mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer OSI PHARMACEUTICALS, INC. 2007-05-17 US disclosed
US-20070112005-A1 mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer OSI PHARMACEUTICALS, INC. 2007-05-17 US disclosed
US-20070112005-A1 mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer OSI PHARMACEUTICALS, INC. 2007-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070123527-A1 3-Amino-1-arylpropyl indoles and aza-substituted indoles and uses thereof IDO1, RB1, AHR BRD4 328/4885AHR 3/4885PRKCI 4174/4885
US-11807635-B2 Nitrile derivative that acts as inhibitor of dipeptidyl peptidase 1 and use thereof DPP4, DPP3, DPP9 BRD4 1323/4885AHR 2129/4885PRKCI 2673/4885
US-20260125364-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS HTR6, HTR3C, OPRD1 BRD4 2384/4885AHR 1249/4885PRKCI 3367/4885
US-11964961-B2 Heteroaromatic compounds and their use as dopamine D1 ligands DRD2, DRD1, HTR1D BRD4 3173/4885AHR 1525/4885PRKCI 4088/4885
US-11773091-B2 6-5 fused rings as C5a inhibitors C5AR1, C5AR2, C3AR1 BRD4 4666/4885AHR 2160/4885PRKCI 3753/4885
US-20240317713-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS DRD2, DRD1, HTR1D BRD4 3173/4885AHR 1525/4885PRKCI 4088/4885
US-20070112005-A1 mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer MTOR, MAPKAP1, RPS6KA1 BRD4 2079/4885AHR 4554/4885PRKCI 306/4885
US-20230373978-A1 HETEROARYL-SUBSTITUTED IMIDAZOLE DERIVATIVES F3, ABL1, CFTR BRD4 309/4885AHR 175/4885PRKCI 2911/4885
US-12595255-B2 Heteroaryl-substituted imidazole derivatives CLIC1, CYP2B6, CYP2D6 BRD4 785/4885AHR 452/4885PRKCI 1301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.